Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19025042 | 0.88 | FOLH1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL10384650 | 0.81 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL332512 | 0.78 | CA12 (0.36) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL319857 | 0.78 | MEN1 (0.35) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL246225 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL3898144 | 0.76 | HTT (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL3397667 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| SCHEMBL24101 | 0.76 | MEN1 (0.34) | MEN1KMT2AHTTL3MBTL1LMNA | |
| Bicarbonate SCHEMBL4130664 | 0.74 | MEN1 (0.33) | MEN1KMT2AHTTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL12487855 | 0.74 | KDM4E (0.37) | MEN1KMT2AHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066292-A1 | CYSTEAMINE AND/OR CYSTAMINE PRODRUGS | UNIV CALIFORNIA (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4457211-A2 | CYSTEAMINE AND/OR CYSTAMINE PRODRUGS | The Regents of the University of California (US) | 2024-11-06 | — | — | EP | disclosed |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2024-10-31 | — | — | US | disclosed |
| EP-4237008-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | Elucida Oncology, Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. | 2023-08-03 | — | — | US | disclosed |
| WO-2023129584-A2 | CYSTEAMINE AND/OR CYSTAMINE PRODRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022093800-A2 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | ELUCIDA ONCOLOGY, INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| CN-106458957-B | Novel cell permeable succinic acid compounds | 爱博利瓦有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | NOVARTIS AG (CH) | 2019-08-06 | — | — | US | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-6504034-B2 | Cell antiproliferative agents; anticancer agents | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020147343-A1 | Naphthostyrils | CHEN YI (US) | 2002-10-10 | — | — | US | disclosed |
| EP-1036059-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2002059109-A2 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN- DEPENDENT KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-01 | — | — | WO | disclosed |
| US-6303659-B2 | Compounds | ASTRAZENECA AB (SE) | 2001-10-16 | — | — | US | disclosed |
| US-6258838-B1 | Compounds | ASTRAZENECA AB (SE) | 2001-07-10 | — | — | US | disclosed |
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
| US-6201024-B1 | EFFECTIVE P2X7 RECEPTOR ANTAGONISTS FOR USE IN THE TREATMENT OF INFLAMMATORY, IMMUNE OR CARDIOVASCULAR DISORDERS | ASTRAZENECA UK LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| EP-1036059-A1 | ADAMANTANE DERIVATIVES | AstraZeneca UK Limited (GB) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029661-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066292-A1 | CYSTEAMINE AND/OR CYSTAMINE PRODRUGS | SLC7A11, FABP1, CBS | MEN1 3097/4885KMT2A 3663/4885HTT 474/4885 |
| US-20020147343-A1 | Naphthostyrils | CCNI, CDKL1, CDK2 | MEN1 2355/4885KMT2A 2197/4885HTT 4212/4885 |
| US-20230241243-A1 | CARRIER PARTICLE-DRUG CONJUGATES, SELF-IMMOLATIVE LINKERS, AND USES THEREOF | NDC1, KIFC1, SDCBP | MEN1 2314/4885KMT2A 4146/4885HTT 1399/4885 |
| US-10369138-B2 | Monobactam organic compounds for the treatment of bacterial infections | MGAM, MGAM2, BPGM | MEN1 1714/4885KMT2A 2273/4885HTT 4722/4885 |
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | MEN1 1930/4885KMT2A 4437/4885HTT 1284/4885 |
| US-20240360149-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | MEN1 41/4885KMT2A 2349/4885HTT 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.